Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MetasTx next-generation KIT inhibitor
- Development stage
- Preclinical
- Lead developer
- MetasTx
- Modality
- Small Molecules
01
Overview
MetasTx is developing a next-generation KIT inhibitor program for the treatment of prostate cancer. This small molecule therapy targets the KIT receptor (also known as c-Kit), a tyrosine kinase that sits upstream of epithelial-to-mesenchymal transition (EMT) and cancer stemness processes. These biological pathways are critical drivers of metastasis and drug resistance in prostate cancer. By inhibiting KIT, the therapy aims to prevent cancer spread and overcome treatment resistance. The program is currently in preclinical development, advancing through assays with the goal of entering IND-enabling work and initiating first-in-human studies by late 2027 or early 2028. MetasTx intends to deploy this therapy as part of a precision oncology platform that includes a companion diagnostic to identify high-risk patients.
- Other names
- next-generation KIT inhibitorsMetasTx KIT inhibitor program
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on MetasTx next-generation KIT inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MetasTx next-generation KIT inhibitor.